Loading...

JBIO JADE BIOSCIENCES INC Operational Disruptions 8-K Filing

JD B

JB

JADE BIOSCIENCES INC

(JBIO)

2024 8-K

Financial Results Announced

Financial Update

Funding Agreement Signed

New Funding Agreement

Management Change

Financial Results Released

Merger of Equals

Investor Meetings

Merger of Equals

Merger Approval

Cash Dividend Announced

Merger Agreement

Cash Dividend Announcement

Merger Agreement

Audit Committee Compliance

Director Resignation

Strategic Review Announcement

Workforce Reduction Plan

Results from Phase 2b Porti...

Annual Meeting of Stockholders

Financial Results Announcement

Corporate Presentation

Financial Results Announcement

Regulation FD Disclosure

Enrollment Completion in IM...

Financial Results Announcement

Financial Results and Busin...

Sales Pursuant to At-the-Ma...

Annual Meeting Results

Financial Results and Busin...

Agreement for ATM Equity Of...

Financial Results Announcement

Appointment of Director

External Links:

Aerovate Therapeutics announced topline results from the Phase 2b portion of IMPAHCT study for the treatment of Pulmonary Arterial Hypertension, which did not meet its primary endpoint or show meaningful improvements in secondary endpoints.

AI Assistant

JADE BIOSCIENCES INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.